MA20150066A1 - Process for the treatment of steroid-responsive dermatoses - Google Patents

Process for the treatment of steroid-responsive dermatoses

Info

Publication number
MA20150066A1
MA20150066A1 MA37430A MA37430A MA20150066A1 MA 20150066 A1 MA20150066 A1 MA 20150066A1 MA 37430 A MA37430 A MA 37430A MA 37430 A MA37430 A MA 37430A MA 20150066 A1 MA20150066 A1 MA 20150066A1
Authority
MA
Morocco
Prior art keywords
chloro
methyl
steroid
treatment
responsive dermatoses
Prior art date
Application number
MA37430A
Other languages
French (fr)
Inventor
Pankaj Agarwal
Vinod Kumar
Qing Xie
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Priority claimed from PCT/EP2013/058249 external-priority patent/WO2013160222A1/en
Publication of MA20150066A1 publication Critical patent/MA20150066A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement de dermatoses répondant aux stéroïdes chez un mammifère, y compris un être humain, en ayant besoin, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un composé choisi dans le groupe constitué par : le n-{(1s)-2-amino-1-[(3-fluorophényl)méthyl]éthyl}-5-chloro-4-(4-chloro-1-méthyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide ou un sel pharmaceutiquement acceptable de celui-ci, et le composé n-{(1s)-2-amino-1-[(3,4-difluorophényl)méthyl]éthyl}-5-chloro-4-(4-chloro-1-méthyl-1h-pyrazol-5-yl)-2- furancarboxamide ou un sel pharmaceutiquement acceptable de celui-ci, à un tel mammifère.The present invention relates to a method of treating steroid-responsive dermatoses in a mammal, including a human being, in need thereof, which comprises administering a therapeutically effective amount of a compound selected from the group consisting of: n - {(1s) -2-amino-1 - [(3-fluorophenyl) methyl] ethyl} -5-chloro-4- (4-chloro-1-methyl-1h-pyrazol-5-yl) -2- thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and the compound n - {(1s) -2-amino-1 - [(3,4-difluorophenyl) methyl] ethyl} -5-chloro-4- (4-chloro) 1-methyl-1H-pyrazol-5-yl) -2-furancarboxamide or a pharmaceutically acceptable salt thereof, to such a mammal.

MA37430A 2012-04-24 2013-04-22 Process for the treatment of steroid-responsive dermatoses MA20150066A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
PCT/EP2013/058249 WO2013160222A1 (en) 2012-04-24 2013-04-22 Treatment method for steroid responsive dermatoses

Publications (1)

Publication Number Publication Date
MA20150066A1 true MA20150066A1 (en) 2015-02-27

Family

ID=54337958

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37430A MA20150066A1 (en) 2012-04-24 2013-04-22 Process for the treatment of steroid-responsive dermatoses

Country Status (1)

Country Link
MA (1) MA20150066A1 (en)

Similar Documents

Publication Publication Date Title
MX2021012669A (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol- 5-yl)-pyridin-3-yl)methoxy)benzaldehyde.
MA35432B1 (en) Compound for the treatment and prophylaxis of respiratory syncytial virus disease
MA47313B1 (en) Her2 antibody subcutaneous formulations
MA38380A1 (en) Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR)
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2013049770A3 (en) Methods of treating cancer
MA37888B1 (en) Coated pharmaceutical composition containing regorafenib
IN2015DN00376A (en)
EA201391263A1 (en) COMBINED THERAPIES OF HEMATOLOGICAL TUMORS
EA201490163A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
WO2013112950A3 (en) Certain chemical entities, compositions, and methods
EA201691402A1 (en) PHARMACEUTICAL PREPARATION CONTAINING A COMPOUND OF THE PYRIDYLAMINOACIC ACID
EA201592254A1 (en) DERIVATIVES OF Pyrazolopyrrolidin-4-IT and THEIR APPLICATION IN THE TREATMENT OF DISEASE
EA201690386A1 (en) COMPOUNDS AND COMPOSITIONS AS MEK INHIBITORS
JP2016501219A5 (en)
MX2018001979A (en) (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrroli dine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl )acrylamide for the treatment of cancer.
WO2010086828A3 (en) Agonist anti-trkb monoclonal antibodies
NZ731751A (en) Method of treating conditions related to the pgi2 receptor
MX2012001708A (en) Humanized anti-amyloid-î oligomer antibody.
MA38307A1 (en) 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohex-3-enecarbaldehyde for the prevention and treatment of cognitive, neurodegenerative or neuronal disease
MX2018011592A (en) Compound having mutant idh inhibitory activity, preparation method and use thereof.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EP4017880A4 (en) Use of brazikumab to treat crohn's disease
MA20150066A1 (en) Process for the treatment of steroid-responsive dermatoses
MX2014011843A (en) Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma.